MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS)

MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS)

Bibliografiske detaljer
Main Authors:	Chen, J, Johnson, L, McKenna, K, Choi, T, Duan, J, Feng, D, Tsai, J, Garcia-Martin, N, Sompalli, K, Maute, R, Vyas, P, Majeti, R, Takimoto, C, Liu, J, Ramsingh, G, Chao, M, Volkmer, J-P, Weissman, I
Format:	Conference item
Sprog:	English
Udgivet:	Elsevier 2022

Lignende værker

P740: IMPACT OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE ON RED BLOOD CELLS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS)
af: J. Y. Chen, et al.
Udgivet: (2022-06-01)

MDS-197: Magrolimab + azacitidine versus azacitidine + placebo in untreated higher-risk (HR) myelodysplastic syndromes (MDS): the phase 3, randomized, ENHANCE study
af: Garcia-Manero, G, et al.
Udgivet: (2021)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study
af: Garcia-Manero, G, et al.
Udgivet: (2021)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study
af: Garcia-Manero, G, et al.
Udgivet: (2021)

MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results
af: Sallman, D, et al.
Udgivet: (2022)

S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS
af: D. A. Sallman, et al.
Udgivet: (2022-06-01)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
af: KS G&ouml;tze, et al.
Udgivet: (2009-10-01)

PB1922: EFFECTIVENESS OF AZACITIDINE IN FRONTLINE HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS): A RETROSPECTIVE COHORT STUDY OF 382 PATIENTS
af: N. Rajakumaraswamy, et al.
Udgivet: (2022-06-01)

Cost-effectiveness of azacitidine compared with low-doses of chemotherapy (LDC) in myelodysplastic syndrome (MDS)
af: Myrna Candelaria-Hernández, et al.
Udgivet: (2017-06-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study
af: Garcia-Manero, G, et al.
Udgivet: (2021)

P699: MAGROLIMAB ALTERS THE TUMOR MICROENVIRONMENT TO IMPROVE BONE MARROW FUNCTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)
af: Lisa Johnson, et al.
Udgivet: (2023-08-01)

RELAPSED UBTF-TD MDS TREATED WITH VENETOCLAX AND AZACITIDINE
af: Henrik Hasle, et al.
Udgivet: (2023-12-01)

PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)
af: A. DeZern, et al.
Udgivet: (2022-06-01)

Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study
af: Sallman, DA, et al.
Udgivet: (2023)

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
af: Stahl, M, et al.
Udgivet: (2023)

P774: CLINICAL OUTCOMES ASSOCIATED WITH AZACITIDINE MONOTHERAPY FOR TREATMENT-NAIVE PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS): A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS
af: K. Hasegawa, et al.
Udgivet: (2022-06-01)

Trisomy X and myelodysplastic syndrome (MDS) with eosinophilia
af: Mohd Tohit, Eusni Rahayu, et al.
Udgivet: (2012)

MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine
af: Massimo Breccia, et al.
Udgivet: (2012-02-01)

Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system
af: Thomas Prebet, et al.
Udgivet: (2016-10-01)

THERAPY-RELATED MYELODYSPLASTIC SYNDROMES (t-MDS) IN CHILDHOOD: THE EXPERIENCE OF THE HELLENIC STUDY GROUP FOR MDS/JMML/SAA, MEMBER OF THE EWOG-MDS/SAA WORKING GROUP
af: Loizos Petrikkos, et al.
Udgivet: (2023-12-01)

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
af: Stefanie Jilg, et al.
Udgivet: (2019-04-01)

PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
af: Amer M. Zeidan, et al.
Udgivet: (2023-08-01)

Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape
af: Daniel Karel, et al.
Udgivet: (2024-04-01)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
af: Josephine Lucero, et al.
Udgivet: (2023-06-01)

Cytogenetic study of Brazilian patients with myelodysplastic syndrome (MDS)
af: Tamara Borgonovo, et al.
Udgivet: (2005-12-01)

Myelodysplastic syndromes (MDS): prognostic factors and scoring systems
af: Elizabeth Xisto Souto, et al.

P743: THE PIVOTAL ROLE OF GLUTAMINOLYSIS IN MYELODYSPLASTIC SYNDROME (MDS): A NOVEL STRATEGY FOR THE TARGETED THERAPY OF MDS
af: S. Okabe, et al.
Udgivet: (2022-06-01)

Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
af: Efficace, F, et al.
Udgivet: (2024)

Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia
af: Dickinson, M, et al.
Udgivet: (2018)

Effect of 5-Azacitidine Treatment on Redox Status and Inflammatory Condition in MDS Patients
af: Paola Montes, et al.
Udgivet: (2022-01-01)

Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
af: Fabio Efficace, et al.
Udgivet: (2024-05-01)

Transformation of myelodysplastic syndrome (MDS) to acute myeloid leukaemia (AML)
af: Goh, Chermaine Yu Zhen
Udgivet: (2021)

EHA Endorsement of the European Guidelines for Myelodysplastic Syndromes, MDS-RIGHT
af: Sabine Blum, et al.
Udgivet: (2021-09-01)

Molecular Drivers of Myelodysplastic Neoplasms (MDS)—Classification and Prognostic Relevance
af: Fieke W. Hoff, et al.
Udgivet: (2023-02-01)

The first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results
af: Sallman, D, et al.
Udgivet: (2021)

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
af: Theo de Witte, et al.
Udgivet: (2020-09-01)

“Low‐risk” myelodysplastic neoplasm (MDS): Time for a name change?
af: Shoshana Burke, et al.
Udgivet: (2025-01-01)

Qualitative flow cytometric analysis of Malaysian myelodysplastic syndromes (MDS) patients.
af: Broojerdi, Mohadese Hashem, et al.
Udgivet: (2012)

Adults Myelodysplastic Syndromes in Algeria: A Study by the Algerian MDS Group
af: Mohamed Amine Bekadja, et al.
Udgivet: (2023-04-01)

Current State and Challenges in Development of Targeted Therapies in Myelodysplastic Syndromes (MDS)
af: Michele Stanchina, et al.
Udgivet: (2021-04-01)